TMCnet News

Research and Markets: Pancreatic Cancer Partnering Deals and Agreements 2010-2015
[April 27, 2015]

Research and Markets: Pancreatic Cancer Partnering Deals and Agreements 2010-2015


Research and Markets (http://www.researchandmarkets.com/research/z4zgqn/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer Partnering 2010-2015" report to their offering.

The Pancreatic cancer Partnering 2010-2015 provides understanding and access to the pancreatic cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of pancreatic cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pancreatic cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.



This data driven report contains over 100 links to online copies of actual pancreatic cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report scope


Pancreatic cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to pancreatic cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in pancreatic cancer dealmaking in the biopharma industry since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 100 pancreatic cancer deals and contract documents where available
  • The leading pancreatic cancer deals by value since 2010

In Pancreatic cancer Partnering 2010-2015, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

Companies Mentioned

  • Actavis
  • Actelion
  • Allergan
  • Amgen
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols
  • Hospira
  • Mitsubishi (News - Alert) Tanabe
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Purdue
  • Roche
  • Teva
  • Valeant
  • Warner Chilcott
  • Watson

For more information visit http://www.researchandmarkets.com/research/z4zgqn/pancreatic_cancer


[ Back To TMCnet.com's Homepage ]